RxDoctor Payments Data

Luis Cousin, MD

Family Medicine · Napa, CANPI 1477664936

Payments from drug & device makers

$1,701in general payments, 2019–2025

Across 103 payments — averaging $16.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$342
  • Pfizer$159
  • Astellas Pharma US Inc$152
  • Boehringer Ingelheim$143
  • Johnson & Johnson$136
  • AbbVie$95
  • plus $675 from 17 others

What the payments were for

  • Food & beverage$1,695100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,701 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$12,427
Medicare patients
37
Services billed
141

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol119$145,362
JardianceEmpagliflozin101$129,277
TradjentaLinagliptin68$79,855
OzempicSemaglutide43$53,201
EliquisApixaban39$52,599
TrulicityDulaglutide27$35,136
MounjaroTirzepatide27$26,912
VivitrolNaltrexone Microspheres16$23,605
JanuviaSitagliptin Phosphate32$22,650
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog45$14,898
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$14,611
DapagliflozinDapagliflozin Propanediol15$9,968
Lantus SolostarInsulin Glargine,hum.Rec.Anlog82$9,766
Aripiprazole12$5,598
Rosuvastatin Calcium225$5,589

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$143$209,132169 claims
AstraZenecaFarxiga$342$145,362119 claims
Lilly USA, LLCTrulicity, Mounjaro$52$62,04854 claims
Novo NordiskOzempic$18$53,20143 claims
PfizerEliquis$159$52,59939 claims
MerckJanuvia$72$22,65032 claims
GSKTrelegy Ellipta$75$14,61123 claims
Sanofi-aventis U.S. LLCLantus$79$2,85922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Napa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →